Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.
Seven patients with gut and pancreatic endocrine tumours have been treated with a long acting somatostatin analogue (SMS 201-995), given as a twice daily subcutaneous injection. This produced dramatic improvement in their endocrine related symptoms, in association with a fall in circulating tumour peptides. One of these patients has now been treated for seven months with this analogue which has controlled his previously life threatening diarrhoea caused by a malignant VIP secreting tumour. He gives his own injections twice daily, and has returned to a full and active life. This is a promising agent both for acute treatment of peptide hypersecretion, and for the long term management of some patients who are unresponsive to other available therapy.
Wood
S M
SM
Kraenzlin
M E
ME
Adrian
T E
TE
Bloom
S R
SR
D000328:Adult; D000368:Aged; D003967:Diarrhea / Q000188:drug therapy; D005260:Female; D005755:Gastrins / Q000097:blood / Q000378:metabolism; D005934:Glucagon / Q000097:blood / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000378:metabolism*; D009384:Paraneoplastic Endocrine Syndromes / Q000097:blood / Q000188:drug therapy*; D010451:Peptide PHI; D010455:Peptides / Q000097:blood / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014660:Vasoactive Intestinal Peptide / Q000097:blood / Q000378:metabolism
D005755:Gastrins; D010451:Peptide PHI; D010455:Peptides; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D005934:Glucagon; D015282:Octreotide